2024-10-23 11:00:00
Not a single politician is missing from the call to denounce the plan for a partial sale by Sanofi of its subsidiary which “produces” Doliprane. Yet is this the right example to illustrate a policy of reindustrialization and health security? Obviously not, for several reasons. The risk of shortage exists for certain medicines, notably anti-infectives and nervous system medicines, but not for paracetamol.
Thus, the construction of two new factories, one by Seqens, which will produce 15,000 tonnes of paracetamol which will be available on the market from 2026, and the other by Ipsophène, in Toulouse, which will produce 4,000 tonnes per year, or, in total, two and a half times European consumption. If there is any concern, it is more about the capacity of the European and global market to absorb such production in the future.
Supply difficulties may exist, but they are linked to our dependence on the active ingredient necessary for the manufacture of paracetamol. This active ingredient was produced in France until 2008, when Rhodia relocated to China. Successive takeovers have paradoxically led a French company, precisely Seqens, to become one of the first producers of paraminophenol (PAP), on Chinese territory, the active ingredient essential for the manufacture of paracetamol, but whose production can be made available. be affected by Chinese export restrictions.
Absence of European medicines policy
Focusing only on the last stage of the manufacturing chain means ensuring our supply of chips by building factories to make them without producing potatoes. The real questions are not asked. The first is that of the consumption of paracetamol by the French. We are the first consumers in Europe with a transformation of our use towards the strongest dosages without any justification (+ 140% over the same period of ten years for the dosage at 1,000 milligrams).
Read also | Article reserved for our subscribers Doliprane: “The creation of a public pharmaceutical capacity would make it possible to guarantee stable production of essential medicines”
Add to your selections
Contrary to what is commonly stated, we have never experienced a real shortage, the supply difficulties at the start of the epidemic due to Covid-19 were linked to the precautionary storage of our compatriots. These difficulties were also resolved in a few weeks with two simple measures, the ban on online sales and the limitation of the number of boxes delivered in pharmacies.
You have 31.56% of this article left to read. The rest is reserved for subscribers.
1729689610
#bad #health #industrial #sovereignty